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A B S T R A C T
Introduction: To determine the beneﬁts of healing therapy (spiritual healing) as an adjunct to
conventional management in irritable bowel syndrome (IBS) and inﬂammatory bowel disease (IBD).
Methods: 200 outpatients with IBS or IBD were randomised to either conventional treatment (control) or
conventional plus ﬁve sessions of healing therapy (intervention). After 12 weeks controls also had healing
therapy. Outcomes used were, the Measure Yourself Medical Outcomes Proﬁle (MYMOP). IBS-QOL, IBDQ,
and symptom measures.
Results: There was a signiﬁcant improvement in the MYMOP score at week 6 (p < 0.001) which was
maintained to week 12 (p < 0.001) and 24 (p < 0.001). Improvements in MYMOP were signiﬁcantly
greater in the intervention group at both 6 (p < 0.001) and 12 weeks (p < 0.001) with effect sizes of 0.7
(95% CI: 0.4–1.1) and 0.8 (95% CI: 0.4–1.2). Condition-speciﬁc data for IBS showed that most QoL
dimensions had a signiﬁcant minimum 10-point score improvement at 6 and 12 weeks. The overall score
improvement was 12.9 units at week 6 (p < 0.001), 12.4 units at week 12 (p < 0.001) and 13.8 units at
week 24 (p < 0.001). In IBD there was also similar score improvement, but only up to week 12 were there
associations of improved social and bowel functions (p < 0.001, respectively). Between group differences
were identiﬁed for QoL scores in IBS at both week 6 (p < 0.001) and 12 (p < 0.001) but only for week 12
(p < 0.001) in the IBD group.
Conclusions: The addition of healing therapy to conventional treatment was associated with
improvement in symptoms and QoL in IBS, and to a lesser extent in IBD.
© 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Irritable Bowel Syndrome (IBS) and Inﬂammatory Bowel
Disease (IBD) are both gastrointestinal disorders of unknown
aetiology that signiﬁcantly reduce quality of life (QoL), impacting
on several aspects of personal, physical, psychological, mobility,Abbreviations: IBS, irritable bowel syndrome; IBD, inﬂammatory bowel disease.
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4.0/).social and employment status (IBS [1–5]) (IBD [6–8]) with high
demands on healthcare resources [9,10]. IBS is considered a
functional disorder with symptoms of abdominal pain or
discomfort with alternating diarrhoea and constipation or a
predominance of either one. It has a community prevalence of
10.5–11.5% [1,5], accounting for 30% of “gut problems” presented in
primary care [11]. IBD includes ulcerative colitis (UC) and Crohn’s
disease (CD) with a UK prevalence rate of 0.25–0.3% for UC and
0.15–0.375% for CD [12,13]. Both are associated with abdominal
pain and diarrhoea marked by episodes of ﬂare-up and periods of
remission resulting in long term morbidity. Furthermore, in UC
there is diffuse mucosal inﬂammation of the colon along with
bloody diarrhoea while CD is characterised by weight loss and
patchy inﬂammation of the intestinal mucosa [14]. There is nole under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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varies between pharmacological drugs, dietary advice and lifestyle
changes, but also surgical treatment in around half of CD patients.
Complementary and Alternative Medicine (CAM) is a holistic
person-centred approach to patient care prevalent in the general
population [18–20]. It covers a wide range of therapies e.g.
acupuncture, massage and herbal medicine, and is accessed by
around 10% of the UK adult population [21] typically to supplement
conventional care [22]. Amongst patients with gastrointestinal
complaints it is estimated that 50% commonly use CAM [23,24].
Around 90% of CAM provision in the UK is purchased privately, the
estimated value of which was £1.6 billion in 2000 [18]; which
excludes NHS and charity-funded CAM usage [25]. Smallwood’s
report into the cost effectiveness of CAM within the NHS concluded
that CAM should be targeted at the effectiveness gaps of
conventional health care [25].
Healing therapy forms part of the energy therapy sub-group of
CAM. Energy therapies are based upon the putative concept that
humans are permeated by subtle energy ﬁelds; imbalances in an
individual’s energy ﬁeld may occur which can be detrimental for
health [26]. Some methods of healing have a long history in their
country of origin, eg spiritual healing in the UK and reiki in Japan.
Others have been developed relatively recently, eg Therapeutic
Touch in the USA. Therapeutic touch is described as “The conscious
use of the hands to direct or modulate, for therapeutic purposes,
selected nonphysical human energies that activate the physical
body” [27]. Because of preliminary experience spiritual healing
was the form of healing therapy evaluated in this study. Spiritual
healing is described as the channelling of energy through the
healer to the patient. In this form of healing therapy, the therapist
need not know of the patient’s symptoms as there is no conscious
direction of therapy. The aim of the therapy is to facilitate self-
healing within the patient.
To the best of the authors’ knowledge, and an electronic search
of medical literature, there have been no previous clinical trials of
healing therapy in either IBS or IBD. There is evidence of healing
therapy stimulating growth of human osteoblastic cells and
inducing differentiation and mineralization [28]; and being
beneﬁcial in pain relief [29], osteoarthritis of the knee [30], burn
patients [31], and ﬁbromyalgia [32]. Other studies on diabetic
neuropathy [33] and asthma [34] did not show any beneﬁt, and a
Cochrane review on wound healing [35] was inconclusive. These
variable results suggest the need to evaluate its efﬁcacy in different
patient groups before adopting it as a therapeutic intervention.
This study aimed to determine the beneﬁts of healing therapy as an
adjunct to conventional management of individuals with IBS and
IBD.
2. Methods
2.1. Trial design
This study was a randomised controlled trial of healing therapy
for people with a clinical diagnosis of IBS or IBD. It was pragmatic
using a two-armed design, comparing the effectiveness of ﬁve
sessions of healing therapy as an adjunct to conventional
treatment against a waiting list control receiving conventional
treatment only. One change regarding the inclusion of CD patients
was made after the original protocol (http://www.isrctn.com/
ISRCTN13039379) was submitted. The allocation ratio was 1:1
(waiting-list: intervention); the computer generated blocked
randomisation list (block size = 6) was stratiﬁed by disease type
(IBS and IBD) to ensure equal allocation to each arm. Allocation was
concealed and randomisation was carried out remotely via
telephone between the hospital based research assistant and
the list controller (co-investigator) once eligibility had beenconﬁrmed and consent achieved. Randomisation took place after
informed consent was achieved and baseline questionnaires had
been completed in the presence of the participant who was then
informed immediately of the outcome. Due to the nature of the
intervention no blinding was possible. At the end of 12 weeks the
waiting list control group also received treatment. This allowed all
participants to receive the intervention. This trial was approved by
The Black Country Research Ethics Committee, West Midlands, UK
(identiﬁer 10/H1202/36), and informed written consent was
obtained by all participants. Formal between-group comparisons
are those undertaken at week 6 and 12, although we report data
from week 24 both to enable the longer-term impact of the
intervention to be assessed in the intervention group and impact
between week 12 and 24 in the waiting list control group.
The trial was conducted at two Birmingham (UK) study sites
located within the Heart of England NHS Foundation Trust.
Participants were recruited from gastroenterology outpatient’s
clinics either through routine appointments or by postal invitation
following retrieval from the patient database. Initially, eligibility
criteria were an age 18 years and over, having attended clinic in the
previous 12 months with a clinical diagnosis of IBS (conﬁrmed by
ROME II criteria) or with a clinician diagnosis of Ulcerative Colitis.
In month 8 due to low recruitment rates this was extended to
include individuals with a clinician diagnosis of Crohn’s Disease to
supplement the IBD group. Exclusion criteria included: having
received healing therapy in the last 6 months; being unable to
provide fully informed consent; being unable to self complete
outcome questionnaires; those engaged in or having completed
another clinical trial in the previous 8 weeks; and pregnant
women.
2.2. The intervention
The intervention consisted of 5 weekly sessions of 30 min of
healing therapy delivered by therapists in addition to usual clinical
management. Participants who failed to attend an appointment
were offered a replacement session. For uniformity of method,
healing therapy was delivered by healers trained in spiritual
healing by, and members of The Healing Trust [36] in a private
consultation room within the hospital. The Healing Trust was
established in 1954. Members undergo a minimum of 2 years of
nationally standardised training and mentoring by a qualiﬁed
member, testimonials and ﬁnal panel assessment. Participants
received healing therapy fully clothed on a clinic couch or seated in
a chair with back support, depending on comfort and/or disability.
Therapy was not standardised but was administered as per
training, each session beginning by the healer lightly placing their
hands on the patient’s shoulders. Thereafter the healer’s hands are
maintained a short distance (10–12 in.) from the participant’s body
gradually working towards the feet and placing the hands there.
With verbal consent, some healers worked with light touch on the
shoulders, feet, arms and legs for short periods of time. Depending
on the therapist, music may have been played to promote a relaxed
atmosphere during the session.
2.3. Data collection
A selection of validated self-report outcome measures were
used, with outcomes recorded at week 0 (baseline), 6, 12, and 24.
Qualitative data were also collected to ensure the full range of
potential experiences were determinable, published in a separate
paper [37]. The primary outcome measure, the Measure Yourself
Medical Outcome Proﬁle (MYMOP) [38], is a validated patient-
centred problem-speciﬁc instrument speciﬁcally developed for use
in the study of complementary and alternative medicine. This
individualised measure has demonstrated greater responsiveness
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requires patients to identify the two most problematic symptoms,
and an activity restricted by health problems. These three items
and the patient’s general well-being are scored by the patient on
seven-point scales for experiences over the preceding week.
Collectively they generate a MYMOP proﬁle (composite mean
score), wherein lower scores indicate less severity/impact of the
condition. The primary outcome of the trial was pre-speciﬁed as
change in MYMOP score and primary analysis compared change in
score for those in the intervention versus waiting list control
groups.
The secondary outcome measures included disease speciﬁc QoL
and symptom severity measures. QoL was evaluated using
validated tools; the IBS-QOL questionnaire [40] and IBDQoL
measure (IBDQ) [41] assessing health related QoL in people with
IBS and IBD respectively. Symptoms were evaluated using the
Birmingham IBS Symptom questionnaire [42], Simple Clinical
Colitis Activity Index (SCCAI) [43] and a modiﬁed version of the
Harvey-Bradshaw Index [44] capturing symptom severity in IBS,
UC and CD respectively. The total scores for measures, and for
dimensions within measures, were achieved by summing the
constituent items except for the MYMOP which produced a mean
as an individual’s proﬁle score. In the case of the QoL measures
(IBS-QoL and IBDQ), scores for dimensions and for totals were
converted to scores out of 100, where a high score indicated better
QoL. The IBS symptom severity measure produced dimension
scores for pain (0–25 scale), constipation (0–15) and diarrhoea (0–
15), and also a composite total (0–55 scale), where lower scores
indicated lesser severity. The UC symptom severity measure
produced a single total score from 0 to 19, where low scores
indicated lesser severity. Similarly, the CD symptom severity
measure produced a total score for which there was no higher
bound, only low scores indicated lesser severity (a score of 13 was
anticipated to be around the top of the scale).
Follow-up data were collected via postal correspondence and
incomplete responses were included for all available data. Where
data are missing this is due to failed response or partial response
from the patient.
2.4. Sampling
The sample size was determined based on power calculations
regarding the primary outcome (MYMOP). Considerations were
also afforded to numbers of participants with IBS and IBD in terms
of ﬁnal sample size estimates. Eighty-ﬁve individuals in each arm
would enable identiﬁcation of a 0.6 unit difference in MYMOP
score change at the 5% signiﬁcance level with 80% power – based
on assumptions from a prior trial of healing therapy [45]. Assuming
around a 10% loss to follow up, we determined to recruit 100
participants in each arm. Of the overall target of 200, 50% were
targeted from the IBS patient group with the remaining 50%
comprising of UC and CD participants. This was done to preserve
power in secondary disease-speciﬁc analyses although it was
acknowledged that small numbers in sub groups would limit the
ability to detect small or moderate effects.
2.5. Statistical analysis procedures
Baseline characteristics were summarised using descriptive
statistics. Analysis of all outcome measures was undertaken on an
Intention-to-Treat (ITT) basis. Per protocol analysis (PPA) was
undertaken comparing waiting list controls with only those
intervention group participants who attended all 5 sessions of
healing therapy (78%). Analysis of the primary outcome (change in
MYMOP score) was undertaken at a combined patient group level,
regardless of disease type. Additional sub-group analyses split databy disease type. Comparative analyses of each of the outcome
measures were conducted using univariate statistics calculated in
SPSS version 19. In the case of MYMOP univariate analyses were
non-parametric due to non-normally distributed data. Compar-
isons of total scores from respective measures were pre-speciﬁed
as demonstrating difference at a signiﬁcance level of p < 0.01;
however, for analysis of sub-scale or dimension scores a stricter
signiﬁcance level of p < 0.005 was speciﬁed due to multiple
testing.
A two level hierarchical model with random intercept was
created for each of the outcome variables (i.e. a patient speciﬁc
regression line where each patient has his/her own regression line
as opposed to a single regression line to represent all the patients)
adjusting for age, gender and years since diagnosis. Difference-in-
differences analysis was conducted using this model in the
statistical package STATA version 12 in order to compare differ-
ences between baseline and 6 and 12 weeks’ outcome scores
between the groups.
Imputations for missing data were undertaken on a case-by-case
basis. A maximum of three missingvalueswere permissible from any
one outcome measure; where more than three values were missing
from a speciﬁc measure, the total score was removed from analysis. A
maximum of two missing values were permissible from any one
dimension or sub-scale (only one allowed for dimensions of three or
fewer items), where more than two items were missing these
dimensions were removed from analysis. When the item(s) was
(were) missing from an outcome measure a mean imputation was
used i.e. a mean score from the completed items or from the
completed dimension items was calculated and inputted.
3. Results
In total, 241 patients expressed an interest in participating in
this trial, from September 2010 to February 2012. A total of 200
(83%) met the eligibility criteria, consented to take part and were
randomised (Fig. 1). Of these, 168 (84%) completed 6 week follow-
up measures, 158 (79%) completed 12 week follow-up measures,
and 143 (72%) completed the 24 week follow-up measures. The
attrition rate was similar across study arms; reasons for attrition
are detailed in Fig.1. Data collection was completed in August 2012.
Table 1 presents baseline characteristics of the study partic-
ipants. Overall, participants had a median age of 46 (IQR 33.0–
62.0), were predominantly female (71%) and non-smokers (87%),
with only a marginally healthy median BMI of 24.0 (IQR 21.0–27.7),
and a diagnosed on average 5 years previously (IQR 1.5 years–10
years). The randomised groups were similar on entry to the trial.
Only one serious adverse event was recorded during the study
period (a TIA) but this was in the context of an ongoing history of
such events and was not deemed to be related to participation.
Although detailed data were not collected on disease history, given
the recruitment context of a secondary care service, all patients,
including those with IBS, have a history of disease states which
could not be managed in a primary care setting.
All available data contributed to analyses. Of those that were
randomised to the intervention arm, 79 (78%) attended all 5
sessions of healing therapy and were included in PPA; a further 12
attended 4 sessions. Two participants failed to attend any sessions.
Treatment was not yet completed at 6 weeks for 42% of
participants.
Baseline MYMOP scores are provided in Table 2, QoL scores are
provided in Tables 3 and 4 for IBS and IBD respectively, and
symptom severity scores by disease group are provided in Table 5.
Baseline scores were generally comparable between groups –
differences were noted in QoL dimension-level scores between
randomisation groups but overall scores did not exhibit such
differences.
Returned express ion of interest form (n=241 )
Eli gible, consented and randomised (n = 200 )
Baseli ne: Intervenon Arm (n=101 ):
IBS (n=54 ); UC (n=35 ); CD (n=12 )
Baseli ne: Waing List Control Arm (n=99 *):
IBS (n=52 *); UC (n=35 ); CD (n=12 )
Wk 6: Intervenon Arm (n=86 ):
IBS (n=47 ); UC (n=30 ); CD (n=9)
Wk 6: Waing List Control Arm (n=82 ):
IBS (n=40 ); UC (n=32 ); CD (n=10 )
Wk 12 : Intervenon Arm (n=79 ):
IBS (n=41 ); UC (n=29 ); CD (n=9)
Wk 12 : Waing List Control Arm (n=79 ):
IBS (n=40 ); UC (n=29 ); CD (n=10 )
Wk 24 : Intervenon Arm (n=75 )
IBS (n=41 ); UC (n=27 ); CD (n=7)
Wk 24 : Waing List Control Arm (n=68 )
IBS (n=32 ); UC (n=27 ); CD (n=9)
Excluded (n=41 ): un avail able du e to other comm itments (n=17 ); no response (n=9); health problems (n=4); repeated 
non-aendance (n=3); not eligi ble (n=2); relocated from area (n=2); other reasons (n=4)
No follow up at week 6 bu t assess ed at wee k 12 (n=13 )
Withd rawn (n=2)
Lost to foll ow up  (n=23 ):
Did not return quesonn aire booklet (n=10 )
Non-contactable (n=13 )
No follow up at week 12  bu t assessed at wee k 24  (n=19)
Withd rawn (n=1)
No follow up at week 6 bu t ass essed at wee k 12  (n=15 )
Withd rawn (n=1)
Lost to foll ow up  (n=23 ):
Did not return quesonn aire booklet (n=14 )
Non-contactable (n=9)
No follow up at week 12  bu t assess ed at wee k 24  (n=12)
Withd rawn (n=6)
Fig. 1. Flow chart of participants. Reasons for withdrawals from trial included the following – serious co-morbid health problem experienced prior to intervention (n = 3);
other commitments (n = 4); contravened protocol (sought therapy outside of trial) (n = 1); felt well so did not consider beneﬁt could be gained (n = 1); change in circumstance
(n = 1). *Disclosure of concurrent trial participation – deemed to be protocol breach and baseline data not considered in analysis.
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The primary outcome was difference between groups in score
change for the patient reported MYMOP measure. As this measure
allows patients to deﬁne the most problematic complaint,
consideration of the reported issues is of value. Overall, responsesTable 1
Baseline characteristics of the participants.
Characteristics Intervention arm
(n = 101)
Diagnosis
IBS 54 (53.5%) 
Ulcerative Colitis 35 (34.7%) 
Crohn’s Disease 12 (11.9%) 
Age (yrs) 44.0 (33.0–60.5) 
Sex (female) 73 (72.3%) 
BMI (weight kg/height m2) 24.8 (22.6–29.3) 
Current smoker 15 (14.9%) 
Drinks alcohol 60 (59.4%) 
Employed (part or full time) 61 (60.4%) 
Length of time since diagnosis (years) 4.5 (1.5–10.0) 
No. of medications (Prescription or OTC) 2.0 (1.0–4.0) 
Values are numbers (percentages) or medians (Interquartile ranges) due to non-normacoded subsequently as ‘physical’ (as opposed to mental) dominated
the self-reported symptoms of participants; ‘pain’ comprised 24%
of all symptom 1 and 2 responses; ‘bowel habit’ was presented as
either symptom 1 or 2 in 17% of cases, other symptoms commonly
reported included ‘diarrhoea’ (10%), ‘cramp’ (8%), and ‘bloating’
(7%). Activities made difﬁcult by their condition were reported andControl arm
(n = 98)
Total
(n = 199)
51 (52.0%) 105 (52.8%)
35 (35.7%) 70 (35.2%)
12 (12.2%) 24 (12.1%)
48.5 (34.0–64.0) 46.0 (33.0–62.0)
69 (70.4%) 142 (71.4%)
23.9 (21.1–27.8) 24.4 (21.0–27.7)
11 (11.2%) 26 (13.1%)
57 (58.2%) 117 (58.8%)
56 (57.1%) 117 (58.8%)
6.0 (2.0–10.0) 5.0 (1.5–10.0)
2.0 (1.0–4.0) 2.0 (1.04.0)
l distributions. OTC = Over the counter.
Table 2
MYMOP scores at baseline and 6-, 12-, and 24 weeks.
Symptom 1 Symptom 2 Activity Wellbeing Proﬁle
C I C I C I C I C I
Baseline
Median (IQR)
4
(3–5)
4
(3–5)
4
(3–5)
4
(3–5)
4
(3–5)
4
(3–5)
4
(3–5)
3
(3–4)
4.25
(3.25–4.75)
4.00
(3.00–4.50)
6 weeks
Median (IQR)
4
(3–5)
3
(2–4)
4
(3–5)
3
(2–4)
4
(2–5)
3
(1–4)
4
(3–5)
3
(2–4)
3.80
(2.80–4.58)
2.60
(1.73–3.58)
p-value* 0.001 <0.001 <0.001 <0.001 <0.001
p-value** 0.374 <0.001 0.765 <0.001 0.009 <0.001 0.793 0.002 0.318 0.001
12 weeks
Median (IQR)
4
(3–5)
2
(1–4)
4
(2–5)
2
(1–4)
4
(3–5)
2
(1–4)
4
(3–4)
3
(1–4)
3.55
(3.00–4.35)
2.35
(1.30–3.85)
p-value* <0.001 <0.001 0.001 0.007 <0.001
p-value** 0.471 <0.001 0.159 <0.001 0.006 <0.001 0.796 0.298 0.324 <0.001
Waiting list control group eligible for intervention at this point (post 12 week)
24 weeks
Median (IQR)
3
(2–4)
3
(1–4)
3
(2–4)
3
(2–4)
2
(1–4)
3
(1–4)
3
(2–4)
3
(2–4)
2.80
(1.78–3.80)
2.75
(1.50–4.00)
P-valueb 0.001 0.001 <0.001 0.001 <0.001 0.001 0.016 0.395 <0.001 0.002
C = (Waiting List) Control Arm. I = Intervention. For maximum n values at baseline and follow-up please refer to Fig. 1. A decline in MYMOP scores indicates improvement in
condition. Reports comparisons of ITT analyses only.
* Univariate (between-group comparison – Wilcoxon Mann-Whitney).
** Univariate (within-group comparison to baseline- Wilcoxon signed rank). 95% Conﬁdence Interval.
Table 3
MYMOP Proﬁle Scores according to disease type irritable bowel syndrome (IBS) or inﬂammatory bowel disease (IBD).
IBS IBD Overall
MYMOP proﬁle MYMOP proﬁle MYMOP proﬁle
C I C I C I
Baseline median 4.50 4.38 3.75 3.25 4.25 4.00
IQR 4.00–5.25 3.69–5.00 1.50–4.50 2.33–4.25 3.25–4.75 3.00–4.50
6 weeks median 4.20 3.20 3.25 2.00 3.80 2.60
IQR 3.30–4.80 2.25–3.80 2.38–4.23 1.30–3.50 2.80–4.58 1.73–3.58
(p-value) within 0.015 <0.001 0.372 0.016 0.318 <0.001
(p-value) between <0.001 0.015 <0.001
12 weeks median 3.80 2.90 3.30 1.80 3.55 2.35
IQR 3.30–4.80 1.80–4.00 2.70–4.58 1.00–3.78 3.00–4.35 1.30–3.85
(p-value) within 0.001 0.000 0.094 0.022 0.324 <0.001
(p-value) between 0.005 0.002 <0.001
24 weeks median 3.00 3.13 2.30 2.30 2.80 2.75
IQR 2.25–4.40 2.08–4.45 1.50–3.30 0.30–3.80 1.78–3.80 1.50–4.00
(p-value) within <0.001 0.007 0.049 0.09 <0.001 0.002
C = (Waiting List) Control Arm. I = Intervention. A decline in MYMOP scores indicates improvement in condition. Reports comparisons of ITT analyses only. Control Group
received Intervention also after week 12.
Univariate (between-group comparison – Wilcoxon Mann-Whitney).
Univariate (within-group comparison to baseline- Wilcoxon signed rank).95% Conﬁdence Interval.
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’social’ (23% – e.g. socialising with friends), or ‘mental’ (6% – e.g.
concentrating, sleeping).
Table 2 reports the median MYMOP item scores at baseline,
6-, 12- and 24-weeks. The intervention group demonstrated a
signiﬁcant improvement in all items of the MYMOP at 6 weeks (all
at p < 0.001 with the exception of well-being, p = 0.002); improve-
ments in all except ‘well-being’ were maintained at 12- (p < 0.001)
and 24 weeks (p = 0.002).
Between-group differences (primary end-point) were signiﬁ-
cant for all items at both 6 and 12 weeks (p  0.001) with the
exception of “well-being” at 12 weeks (p = 0.007). At 24 weeks the
waiting list control group (having then received the intervention)
demonstrated signiﬁcant improvements from baseline similar to
those exhibited by the intervention group in week 6. At this point
all between group differences were removed. After adjusting for
age, gender and years since diagnosis, the difference-in-difference
analysis between control and intervention from baseline, reportedITT effect sizes of 0.7 (95% CI 0.4–1.1) and 0.8 (95% CI 0.4–1.2) at 6
and 12 weeks, respectively. The adjusted PPA effect sizes presented
an almost exact same pattern of results. Improvements greater
than 0.5 units potentially confer notable beneﬁt to the individual
[46].
3.2. MYMOP: sub-group analysis
Table 3 reports MYMOP data according to disease type, irritable
bowel syndrome (IBS) or inﬂammatory bowel disease (IBD). The
intervention groups, both IBS and IBD demonstrated a signiﬁcant
improvement in MYMOP at 6 weeks maintained at 12, and 24
weeks.
Between-group differences were signiﬁcant at both 6 and 12
weeks. At 24 weeks the waiting list control group (having now
received the intervention) demonstrated signiﬁcant improve-
ments from baseline similar to those exhibited by the intervention
group in week 6 in both IBS and IBD groups.
Table 4
Irritable Bowel Syndrome Quality of Life scores at baseline and 6-, 12-, and 24 weeks.
Overall Dysphoria Interference
with activity
Body image Health worry Food
avoidance
Social
reaction
Sexual
functioning
Relationships
C I C I C I C I C I C I C I C I C I
Baseline 40.5
(2.6)
45.5
(3.0)
34.7
(2.9)
39.0
(3.7)
37.2
(3.1)
42.9
(3.5)
47.3
(3.9)
53.4
(3.9)
42.3
(3.0)
48.8
(3.0)
24.5
(3.1)
26.8
(3.6)
45.5
(3.7)
50.6
(3.7)
52.4
(5.0)
57.7
(4.8)
55.1
(3.9)
60.3
(3.4)Mean (SE)
6 weeks 43.0
(3.1)
59.4
(3.3)
40.9
(3.6)
57.3
(3.9)
40.2
(3.8)
57.8
(4.0)
49.0
(3.9)
62.1
(4.1)
47.1
(4.1)
59.4
(3.4)
22.5
(3.4)
39.3
(4.2)
45.0
(4.0)
62.8
(3.7)
50.7
(5.5)
69.5
(4.8)
58.7
(4.1)
71.3
(3.2)Mean (SE)
Change from baseline to
6weeks
3.1
(1.7)
12.9
(2.2)
6.6
(2.3)
17.3
(3.3)
3.3
(2.4)
13.3
(2.6)
2.6
(2.5)
8.3
(2.7)
5.8
(2.4)
10.0
(3.0)
0.2
(2.2)
12.3
(3.1)
1.4
(2.6)
9.9
(2.8)
2.1
(3.0)
10.4
(3.7)
3.7
(3.3)
10.3
(2.6)
Mean (SE)
P-value* 0.001 0.003 0.002 0.023 0.016 0.003 0.002 0.012 0.017
Between group difference
(95% CI)
7.2–25.5 5.7–27.1 6.5–28.6 1.8–24.4 2.4–22.3 5.8–27.8 7.0–28.6 4.2–33.3 2.3–22.7
12 weeks 47.7
(2.9)
60.0
(3.9)
45.5
(3.5)
60.9
(4.6)
43.3
(3.4)
55.8
(4.0)
50.7
(3.6)
63.3
(4.2)
51.5
(3.6)
60.5
(4.3)
29.8
(3.8)
40.4
(4.6)
50.2
(4.0)
63.0
(4.1)
53.9
(5.3)
69.6
(5.2)
64.6
(3.6)
70.8
(3.8)Mean (SE)
Change from baseline to
12weeks
5.1
(2.0)
12.4
(2.7)
8.6
(2.7)
18.3
(3.5)
4.6
(2.2)
11.4
(2.8)
1.3
(2.7)
6.4
(2.9)
7.5
(2.8)
11.1
(3.5)
4.4
(3.0)
11.4
(4.0)
3.0
(3.0)
10.8
(2.9)
4.4
(3.7)
12.5
(3.7)
6.0
(3.1)
6.7
(3.1)
Mean (SE)
P-value* 0.013 0.009 0.021 0.026 0.112 0.076 0.027 0.039 0.234
95% CI 2.7–21.9 4.0–26.9 1.9–22.9 1.6–23.6 2.2 to 20.2 1.1 to 22.5 1.5–24.2 0.8–30.5 4.1 to 16.6
Waiting list control group eligible for intervention at this point (post 12 week)
24 weeks 52.6
(4.2)
62.8
(3.8)
51.8
(4.7)
64.5
(4.5)
49.6
(4.7)
57.8
(4.4)
53.9
(4.7)
63.6
(4.0)
57.0
(4.6)
64.6
(4.0)
36.7
(4.4)
42.9
(4.7)
54.7
(4.9)
67.8
(4.3)
54.9
(6.1)
70.3
(5.2)
63.3
(4.5)
76.2
(3.5)Mean (SE)
Change from baseline to
24weeks Mean (SE)
10.1
(2.5)
13.8
(2.8)
15.0
(3.5)
21.1
(3.8)
11.7
(3.0)
12.2
(2.9)
5.9
(2.8)
4.8
(2.9)
11.5
(2.7)
13.6
(3.2)
10.7
(3.8)
13.5
(3.3)
7.6
(3.5)
13.7
(3.8)
10.3
(3.9)
14.2
(4.8)
4.2
(2.5)
11.3
(2.7)
C = (Waiting List) Control Arm. I = Intervention. For maximum n values at baseline and follow-up please refer to Fig. 1. Outcome and dimension scores have been converted to
scores out of 100. A high score denotes higher QoL rating. Positive changes in values between time points indicate an improvement in QoL; Changes calculated using baseline
data from only those cases that provided follow-up data. Table reports comparisons of ITT analyses only.
* Univariate (between-group comparison) with 95% CI indicating the between group difference in change.
Table 5
IBD Quality of Life outcome scores at baseline and 6-, 12-, and 24 weeks.
Overall Emotional function Bowel Function I Bowel Function II Social Function Systemic Function
C I C I C I C I C I C I
Baseline 63.9
(2.9)
62.3
(3.2)
65.2
(2.6)
63.9
(3.1)
61.6
(3.4)
60.3
(4.1)
62.4
(4.0)
56.4
(3.8)
73.9
(3.5)
74.5
(3.8)
51.9
(4.1)
46.8
(4.0)Mean (SE)
6 weeks 66.5
(3.0)
72.0
(3.5)
67.9
(2.6)
74.6
(3.1)
62.1
(3.9)
68.7
(4.4)
61.4
(4.1)
64.5
(4.4)
78.9
(3.5)
84.6
(3.7)
53.7
(4.3)
57.8
(4.4)Mean (SE)
Change from baseline to 6 weeks Mean
(SE)
1.7 (1.2) 7.0 (2.5) 1.8 (1.3) 7.5 (2.4) 0.8
(2.3)
6.1 (3.4) 1.5
(1.8)
7.5 (3.9) 3.9 (2.3) 5.5 (2.4) 0.7 (2.5) 9.1 (4.2)
P-value* 0.229 0.105 0.264 0.601 0.265 0.501
Between group difference
95% CI 3.6 to 14.7 1.4 to 14.8 5.1 to 18.3 8.8 to 15.1 4.4 to 15.8 8.0 to 16.3
12 weeks 65.0
(2.7)
76.1
(2.6)
65.3
(2.6)
74.3
(2.6)
61.1
(3.8)
75.4
(3.3)
61.7
(3.6)
73.6
(3.6)
78.0
(3.3)
89.5
(2.1)
49.2
(3.6)
57.1
(4.8)Mean (SE)
Change from baseline to 12 weeks Mean
(SE)
0.6 (1.9) 10.0
(2.4)
1.2
(2.2)
6.8 (2.3) 1.9
(3.0)
11.6
(3.0)
2.1
(3.3)
14.2
(3.3)
2.8 (2.5) 10.3
(3.0)
2.2
(3.8)
6.0 (3.9)
P-value* 0.004 0.018 0.006 0.022 0.005 0.19
95% CI 3.6–18.5 1.6–16.4 4.3–24.4 1.8–22.2 3.7–19.3 4.0 to 19.8
Waiting list control group eligible for intervention at this point (post 12 week)
24 weeks 74.6
(2.1)
72.8
(3.2)
74.7
(2.2)
73.6
(2.7)
71.9
(3.2)
70.0
(4.5)
72.7
(3.7)
70.5
(4.1)
88.8
(2.3)
86.3
(3.5)
58.0
(3.5)
54.9
(5.1)Mean (SE)
Change from baseline to 24 weeks Mean
(SE)
8.6 (2.5) 6.0 (2.9) 8.0 (2.6) 4.6 (2.6) 7.5 (3.6) 7.6 (3.7) 8.1 (2.9) 9.6 (4.1) 11.3
(2.9)
4.0 (3.7) 6.9 (4.2) 3.8 (5.5)
C = (Waiting List) Control Arm. I = Intervention. For maximum n values at baseline and follow-up please refer to Fig.1. Bowel function I = bowel movements and use of facilities;
Bowel function II = general bowel symptoms. Outcome and dimension scores have been converted to scores out of 100. A high score denotes higher QoL rating. Positive
changes in values between time points indicate an improvement in QoL; Changes calculated using baseline data from only those cases that provided follow-up data. Reports
comparisons of ITT analyses only.
* Univariate (between-group comparison) with 95% CI indicating the between group difference in change (Levene's test for equality signiﬁcant (p = 0.005) so conservative
estimate used).
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3.3.1. Quality of life
Table 4 reports the mean QoL scores at baseline, 6-, 12- and
24- week follow-up for those with IBS. There were signiﬁcant
improvements from baseline overall scores for the interventiongroup, which were sustained at each follow-up point: 6 week (12.9
point improvement, 95% CI 8.5–17.3, t = 5.874, p < 0.001), 12 week
(12.4 point improvement, 95% CI 7.0–17.8, t = 4.666, p < 0.001), and
24 week (13.8 point improvement 95% CI 8.2–19.4, t = 4.982,
p < 0.001). After adjusting for age, gender and years since
diagnosis, the difference-in-difference analysis between total
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reported ITT effect sizes of 10.7 (95% CI 5.3–16.1) and 7.6 (95% CI
0.9–14.2) at 6 and 12 weeks, respectively. The per protocol analysis
effect sizes were larger: 12.6 (95% CI 6.7–18.4) and 10.4 (95%
CI 3.6–17.1) at 6 and 12 weeks respectively.
Referring back to Table 4, all dimensions of QoL within the
intervention group exhibited at least a 10-point improvement at
week 12, maintained to week 24, with the only exceptions being
‘body image’ and ‘relationships’ which demonstrated smaller
improvement. Improvement in the ‘body image’ dimension was
not signiﬁcant beyond week 6 using the criteria for signiﬁcance
pre-speciﬁed for sub-domains. The control group also demon-
strated a moderate improvement of 5.1 points by week 12 (95% CI
1.1-9.0, t = 2.581, p = 0.01), although only the ‘dysphoria’ subscale
demonstrated a signiﬁcant improvement in this group (8.6 point
improvement at week 12, 95% CI 3.2–14.0, t = 3.199, p = 0.003).
Overall, improvements identiﬁed in the control group scores were
consistently smaller than the intervention comparators.
Between-group differences were signiﬁcant at week 6 for the
overall score (p = 0.001) and dimensions of ‘social reaction’, ‘food
avoidance’, ‘interference with activity’ and ‘dysphoria’ (all at
p < 0.005). Between-group differences were not demonstrated at
week 12 for overall scores (p = 0.013) using the pre-speciﬁed
threshold of signiﬁcance or sub-scale scores (p > 0.005), although
all scores maintained improvement from baseline. At 24 week
follow-up (post–treatment) the waiting list control group demon-
strated a larger and signiﬁcant improvement in overall QoL scores
(95% CI 5.0–15.2, t = 4.045, p < 0.001).
When considering QoL in the IBD groups a similar pattern
emerged (Table 5). The intervention group demonstrated signiﬁ-
cant improvement in overall QoL score at week 6 (95% CI = 1.9–12.1,
t = 2.79, p = 0.008) and week 12 (95% CI = 5.2–14.9, t = 4.166,
p <0.001), but did not maintain improvement from baseline at
week 24 (95% CI = 0.2–11.9, t = 2.098, p = 0.044). Change in speciﬁc
dimension scores indicated that social function and bowel function
may have driven this change, as they both present scoreTable 6
Symptom severity outcome scores at baseline and 6-, 12-, and 24 weeks.
Irritable Bowel Syndrome 
Total Pain (subscale) Const
(subs
C I C I C 
Baseline 23.6 (1.0) 23.1 (1.1) 8.7 (0.5) 8.0 (0.5) 5.3 (0
Mean (SE)
Week 6 22.1 (1.0) 15.9 (1.1) 8.4 (0.6) 5.5 (0.4) 5.7 (0
Mean (SE)
Change from baseline to 6 weeks 1.8 (0.9) 6.1 (1.0) 0.7 (0.4) 2.0 (0.4) 0.2 
Mean (SE)
P-value* <0.001 <0.001 0.229
Between group difference
(95% CI) 9.1 to 3.2 4.2 to 1.5 2.7 
Week 12 20.8 (1.2) 16.5 (1.3) 7.5 (0.6) 5.9 (0.6) 5.4 (0
Mean (SE)
Change from baseline to 12 weeks 3.0 (1.0) 5.5 (1.1) 1.4 (0.5) 1.4 (0.4) 0.4 (0
Mean (SE)
P-value* 0.018 0.048 0.312
CI 7.7 to 0.7 3.3 to 0.0 2.5 
Waiting list control group eligible for intervention at this point (post 12 week)
Week 24 19.0 (1.5) 17.8 (1.4) 6.8 (0.6) 6.0 (0.6) 5.3 (0
Mean (SE)
Change from baseline to 24 weeks 4.4 (1.5) 4.1 (1.2) 1.8 (0.7) 1.1 (0.5) 0.5 (0
Mean (SE)
C = (Waiting List) Control Arm. I = Intervention. For maximum n values at baseline and fo
Score ranges for outcome measures: IBS total score (0–55): IBS pain (0–25), IBS const
calculated using baseline data from only those cases that provided follow-up data. Repimprovements of more than 10 points. As observed in the IBS
group, the IBD control group demonstrated a marginal increase in
overall scores at 12 weeks (0.6 point improvement), however this
was not considered a signiﬁcant change (CI 3.4 to 4.5, t = 0.290,
p = 0.773). No signiﬁcant changes in subscale scores were observed
either. The between-group differences in overall scores were
signiﬁcant at week 12 (p = 0.004) only.
After adjusting for age, gender and years since diagnosis, the
difference-in-difference analysis between total scores for control
and intervention participants from baseline reported ITT effect
sizes of 5.8 (95% CI 0.2–11.4) and 10.1 (95% CI 4.3–15.9) at 6 and 12
weeks, respectively. The adjusted PPA effect sizes presented a
similar pattern of results.
3.3.2. Severity of symptoms
Table 6 reports the different symptom severity measures for
each disease type at baseline, 6-, 12- and 24-week follow-up. For
IBS groups improvement in severity scores was signiﬁcantly
different between the intervention group and the waiting list
controls at week 6 (1.8 point improvement in controls versus 6.1 in
intervention, p < 0.001). This seems primarily attributable to the
difference in F scores at this point. Between-group differences
were also observed at week 12 but to a lesser extent (total score
change 3.0 control versus 5.5 intervention, p = 0.018). After
adjusting for age, gender and years since diagnosis, the differ-
ence-in-difference analysis between control and intervention total
scores from baseline reported ITT differences of 4.3 (95% CI 1.9–6.9)
and 2.8 (95% CI 0.1 to 5.7) at 6 and 12 weeks, respectively. The
adjusted PPA effect sizes presented a similar pattern of results. In
the light of baseline scores of around 23 units this is likely to reﬂect
a clinically determinable effect.
Symptom severity scores in those with IBD showed no
signiﬁcant between-group differences in scores at 6- or 12- weeks
despite a consistent trend towards greater improvement in the
intervention group. After adjusting for age, gender and years since
diagnosis, the difference-in-difference analysis between controlUlcerative Colitis Crohn’s Disease
ipation
cale)
Diarrhoea
(subscale)
Total Total
I C I C I C I
.6) 5.4 (0.5) 9.7 (0.6) 9.8 (0.8) 4.7 (0.5) 4.3 (0.5) 6.7 (1.1) 8.5 (1.6)
.6) 4.6 (0.6) 8.1 (0.8) 5.7 (0.6) 4.4 (0.5) 3.8 (0.5) 5.5 (1.1) 7.9 (2.3)
(0.5) 0.8 (0.4) 1.3 (0.2) 3.3 (2.1) 0.1 (0.4) 0.4 (0.4) 0.9 (0.8) 0.8 (0.7)
 0.018 0.410 0.366
to 0.7 4.4 to 0.4 2.2 to 0.9 2.8 to 7.6
.6) 4.6 (0.6) 7.8 (0.8) 6.1 (0.7) 4.5 (0.5) 3.1 (0.5) 6.6 (1.0) 7.0 (1.3)
.5) 1.1 (0.5) 1.3 (0.5) 3.0 (0.5) 0.2 (0.3) 0.7 (0.4) 0.4 (1.0) 1.9 (1.7)
 0.093 0.046 0.808
to 0.8 3.7 to 0.3 2.9 to 0.0 3.0 to 3.8
.7) 4.6 (0.7) 6.8 (0.9) 7.2 (0.8) 3.5 (0.5) 3.4 (0.5) 4.3 (1.4) 4.4 (1.6)
.7) 0.7 (0.6) 2.1 (0.7) 2.2 (0.6) 0.7 (0.5) 0.4 (0.3) 0.5 (0.8) 1.0 (1.6)
llow-up please refer to Fig. 1. Decrease in scores indicates improvement in severity.
ipation (0–15), IBS diarrhoea (0–15); UC total (0–19); CD total (0–13 + ). Changes
orts comparisons of ITT analyses only.
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of 0.3 (0.8 to 1.3 at 95% CI) and 0.6 (0.5 to 1.6 at 95% CI) at 6 and
12 weeks, respectively. The adjusted PPA effect sizes presented a
similar pattern of results. Due to the relatively small numbers
within the Crohn’s disease group no further analysis is reported
here.
4. Discussion
This is the ﬁrst randomised controlled trial to examine the
beneﬁts of healing therapy as an adjunct to conventional
management of individuals with IBS and IBD. The results
demonstrate that when used alongside standard medical care
healing therapy confers additional beneﬁt. Beneﬁts observed in our
IBS cohort in terms of both symptom reduction and QoL
improvement were signiﬁcant, consistent and of size likely to be
associated with ‘clinical beneﬁt’. Observations within the IBD
cohort suggested beneﬁt in some sub-domains but lacked the
strength of association or consistency over measures and time
points observed in the IBS group.
QoL was considerably enhanced in the IBS intervention group
with improvements in emotional states, socialization, and activity
levels which were maintained up to week 24 and were signiﬁcantly
different from controls. Parallel to observations made in the
MYMOP data, there was a meaningful improvement in the QoL
scores for the control group once they also received the
intervention. QoL improvements in the IBD group were noted
but these did not differ between the intervention and control
groups.
When evaluated collectively using the MYMOP, all symptom
and activity measures (except for well-being) showed improve-
ments which were maintained up to week 24, suggesting the
possibility of longer term beneﬁts beyond the period of therapy.
Changes in scores were of a size with the potential to result in
notable improvements to the patient. Failure to demonstrate
beneﬁts to general well-being despite improved symptoms and
activity may be attributed to other factors which have greater
impact on well-being than symptoms and activity or could
represent a time lag factor whereby general perceptions of well-
being are accrued after a period of reduced symptoms. Improve-
ments in MYMOP scores were seen in both IBS and IBD groups.
In this clinical trial we have studied two distinct gastrointesti-
nal syndromes with similar symptoms yet contrasting aetiologies,
IBS, a functional syndrome and IBD a bona ﬁde organic disease. We
have observed that healing therapy is beneﬁcial both in terms of
improvement in patient perception of disease impact (determined
by MYMOP) which was our pre-speciﬁed primary outcome. In IBS
this MYMOP change appeared related to both improved QoL and
symptom improvement. In IBD the MYMOP improvement is less
clearly deﬁned as neither QoL or symptom scores differed between
intervention and control groups. This study does not address the
mechanism of this effect, nor the magnitude of the placebo effect.
Use of “sham” therapy would not provide adequate placebo control
because of the impact of the ‘actor’ having an unintended
therapeutic effect on participants through such a mechanism as
unintended channelling of energy. Small improvements observed
in the control group during the waiting period could be explained
as a Hawthorne effect. The control group continued to have
signiﬁcantly poorer proﬁle scores throughout this period which
subsequently improved once they received the intervention. Per
protocol analyses suggested that greater beneﬁt was associated
with compliance further supporting the observed ﬁndings.
As a whole, physical symptoms dominated, with pain being the
most common, experienced by nearly a quarter, and around one-
ﬁfth had difﬁculties with bowel habit. Condition-speciﬁc data
collected from IBS-QOL and IBDQ questionnaires showed thatsymptom severity score improvements in IBS groups were largely a
result of improvement in pain levels. Variation in levels of
symptom beneﬁt reported between IBS and IBD may be explained
by the dissimilar disease pattern between the two conditions. It is
well known that in IBS added to the biological factor, there is a
strong interplay of psychological and social factors [47,48] that
inﬂuence severity. These ﬁndings may suggest that conditions
linked to functional disorders could accrue greater beneﬁt from
healing therapy. Whether the differential impact of healing
observed in this study is an artefact of a greater placebo response
in individuals with functional disorders will require further study,
although we would argue that the size of the improvement in this
group would make healing a useful therapeutic approach
irrespective of mechanism of action. Our intention was not to
attempt to deﬁne mode of action but to explore from a pragmatic
perspective whether the addition of healing therapy could accrue
patient beneﬁt.
Previous studies on healing therapy (includes healing therapy,
Therapeutic Touch and reiki) have been undertaken on a range of
conditions and symptoms, including cancer, chronic pain
conditions, anxiety, wound healing and HIV, comparing its efﬁcacy
with other complementary therapies as well as standard medical
care. Results from this study are analogous to the conclusions made
by these previous studies which generally support the effective-
ness of healing therapy to reduce pain, anxiety and improved QoL
[29,49,50].
We found no evidence of harm from healing therapy; many
patients found it an interesting and enjoyable experience and
qualitative patient experience data has been collected for further
analysis. Further cost-effectiveness evaluation is required before
determining the role healing therapy may play in resource
restricted health services. Patients with IBS and IBD seen in
secondary care, who remain symptomatic despite the best medical
care, should be considered for healing therapy where this is
available with the understanding that beneﬁt is likely to be greater
in individuals with IBS. It is of note however that participants in
this trial were all recruited from secondary care and therefore the
IBS represented is atypical (having failed primary care manage-
ment), therefore additional treatment strategies for this difﬁcult to
manage sub-group of patients are highly desirable. Conventional
drugs are aimed at suppressing symptoms, but we are now much
more aware that symptom management is not limited only to the
prescription of drugs [49]. This study has demonstrated that
clinically there is beneﬁt to be gained from inclusion of healing in
the management of IBS which has not responded to conventional
management. Research in IBS also recognises that due to its non
homogeneous population not all treatments may be suitable for all
patients [51], something which has been observed in this study and
could be a consideration for future studies.
4.1. Limitations
Generalisability of the study is limited to the self-selective
nature of the participants into the trial, amongst who may be
patients that already have an afﬁnity for complementary therapies,
or have a previous positive experience of healing or other similar
type of therapy. Admittedly, both of these offer a potential bias
towards therapeutic gain. However, ﬁndings from our associated
qualitative [37] work reveal that patients who volunteered for the
trial were not necessarily non-sceptics of the complementary
therapy approach, and anecdotal ﬁndings also suggest that many
had not tried such therapies before. This study is also subject to
biases inherent in trials where blinding has not been achieved. The
decision to utilise a pragmatic trial design with waiting list control
was made after careful consideration. It has been suggested that
trials which use a ‘sham’ therapist are subject to the impact of the
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this along with ethical considerations drove this decision.
Furthermore we wished only to determine whether adding healing
to usual care of patients would offer improvements rather than
demonstrate which of the component parts of a complex
intervention offered beneﬁt. However there remains the possibili-
ty that beneﬁt in the healing arms was entirely attributable to a
placebo effect. There is further possibility that waiting list patients
who were aware of the nature of the intervention offered may have
demonstrated a nocebo response. It has been indicated in the
context of trials used in psychological and behavioural research
that patients on the waiting control trial list: “appear to improve
less (or not at all) than would be expected for people who are
concerned about their behaviour and who are taking steps to
change” [52] and it is also therefore a possibility that those in the
waiting list group deferred taking personal action to alleviate
symptoms. Interestingly in the current study there was a
consistent tendency towards improvement in the control group.
Such a ﬁnding is not unusual and is typically explained by
regression to the mean or the accepted positive impacts of trial
participation. This observation does perhaps support the fact that
simple provision of attention and interest in symptoms and illness
experiences has a positive impact. The fact that improvements in
IBS were not fully replicated in IBD patients may also hint towards
a placebo element to the observed effect although this in no way
discredits the ﬁndings of this trial. The dissimilarities between UC
and CD increase the challenges to study these conditions
collectively under the umbrella of IBD and the small number of
patients with CD in this study would also skew the overall picture
for IBD suggesting different results may be demonstrated if each of
these groups is studied separately with an adequate sample size.
Whilst the decision to include CD after commencement of the trial
to ensure IBD target numbers were achieved we acknowledge that
this more heterogeneous group may have reduced the ability to
identify beneﬁts within an IBD sub-group.
5. Conclusion
This pragmatic trial demonstrates that patient beneﬁt is
accrued through the addition of healing therapy to conventional
management of both IBS and IBD. The greatest beneﬁt was
observed in individuals with IBS where differences which would
confer a clinically determinable beneﬁt were observed. The beneﬁt
observed may at least be, in part, a placebo effect although the size
of beneﬁts observed suggests an alternative mechanism and the
value of any mechanism should arguably not be discounted where
it confers symptomatic relief.
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